A randomized, placebo‐controlled, dose‐escalation phase I/II multicenter trial of low‐dose cidofovir for BK polyomavirus nephropathy

• Published in: Transplant infectious disease Vol. 26; no. 6; pp. e14367 - n/a
• Main Authors: Imlay, Hannah, Gnann, John W., Rooney, James, Peddi, V. Ram, Wiseman, Alexander C., Josephson, Michelle A., Kew, Clifton, Young, Jo‐Anne H., Adey, Deborah B., Samaniego‐Picota, Milagros, Whitley, Richard J., Limaye, Ajit P.
• Format: Journal Article
• Language: English
• Published: Denmark Wiley Subscription Services, Inc 01.12.2024; John Wiley and Sons Inc
• Subjects: Adult; Aged; Allografts; Antiviral Agents - administration & dosage; Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; Antiviral drugs; Biopsy; BK virus; BK Virus - physiology; Case reports; Cidofovir; Cidofovir - administration & dosage; Cidofovir - therapeutic use; Cytosine - administration & dosage; Cytosine - adverse effects; Cytosine - analogs & derivatives; Cytosine - therapeutic use; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glomerular filtration rate; Glomerular Filtration Rate - drug effects; Humans; In vitro methods and tests; Kidney Diseases - virology; kidney transplant; Kidney transplantation; Kidney Transplantation - adverse effects; Male; Middle Aged; Nephropathy; Organophosphonates - administration & dosage; Organophosphonates - adverse effects; Organophosphonates - therapeutic use; Original; Placebos; Polyomavirus Infections - drug therapy; Polyomavirus Infections - virology; randomized controlled trial; Renal failure; Treatment Outcome; Tumor Virus Infections - drug therapy; Tumor Virus Infections - virology; cidofovir; kidney transplant; BK virus; randomized controlled trial

Background BK polyomavirus‐associated nephropathy (BKPyVAN) is an important cause of allograft dysfunction and failure in kidney transplant recipients (KTRs) and there are no proven effective treatments. Case reports and in vitro data support the potential activity of cidofovir against BK polyomavir...